Sulfo-SPDB-DM4 CAS:1626359-59-8 is a state-of-the-art drug-linker conjugate specifically designed for the development of antibody-drug conjugates (ADCs) in cancer therapy. This innovative compound features the potent maytansine-based payload DM4, an antitubulin agent, coupled to a highly efficient and water-soluble sulfo-N-succinimidyl-4-(2-pyridyldithio)butanoate (sulfo-SPDB) linker. The unique combination of DM4 and the sulfo-SPDB linker allows for targeted delivery of the cytotoxic agent, resulting in robust anti-tumor activity.
Applications:
Sulfo-SPDB-DM4 is a versatile research tool with potential applications in the design and optimization of ADCs for cancer therapy. Its superior conjugation efficiency, stability, and water solubility make it an ideal candidate for the development of next-generation targeted drug delivery systems. The powerful DM4 payload, an antitubulin agent, disrupts microtubule dynamics, leading to cell cycle arrest and subsequent apoptosis in targeted cancer cells. By leveraging the unique properties of sulfo-SPDB-DM4, researchers can explore new avenues for targeted cancer therapeutics, contributing to the advancement of more effective and safer treatments for various malignancies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
